Introduction {#Sec1}
============

Metabolic and storage diseases are a diverse group of conditions that are characterised by underlying biochemical or metabolic dysfunctions. Most of these diseases are uncommon or rare. Pulmonary disease in affected patients is most commonly a facet of systemic disease. The more common metabolic lung diseases include pulmonary calcification and ossification, pulmonary alveolar microlithiasis, pulmonary amyloidosis and pulmonary alveolar proteinosis (PAP). Storage diseases are rare in most clinical practices, and patients usually present with multiorgan involvement. Pulmonary involvement in storage diseases occurs in Niemann-Pick disease, Gaucher disease and Hermansky-Pudlak syndrome.

In this review, we describe the radiographic and high-resolution computerised tomography (HRCT) findings of these disorders and include discussion of pathophysiology, pertinent clinical features and the relevant different diagnosis. The key features of these metabolic and storage disorders are summarised in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, emphasising the value of clinical-radiological correlation in reaching an accurate diagnosis. Knowledge of these diseases and their respective imaging appearances is important for radiologists and clinicians, particularly those involved in respiratory care.Table 1Summary of metabolic lung diseasesDiseaseAetiologyPathologyRelevant clinical featuresImaging findingsCXRCT**Pulmonary calcification**Dystrophic or metastatic mechanismsDeposition of calcium in the alveolar septaOften asymptomaticUsually non-diagnosticNumerous subcentimetre calcified nodules**Pulmonary ossification** Nodular formChronic passive congestionCalcified/ossified intra-alveolar massesOften asymptomaticUsually non-diagnosticMid to lower lung predominant 1-5 mm calcified nodules Dendriform formUnclear, occurs in areas of chronic lung insultBranching calcifications affecting the interstitiumOften asymptomaticSerpentine opacitiesCharacteristic lower lobe predominant branching delicate calcifications, often in areas of fibrosis  **Pulmonary alveolar microlithiasis**Unclear, association with *SLC34A2* geneIntra-alveolar deposition of microlithsOften asymptomatic, occurs in all age groupsDiffuse small calcified nodules, giving a "sandstorm" appearance. Lucent subpleural lineDiffuse uniform calcified micronodules with a lower lung predominance  **Pulmonary amyloidosis**Extracellular deposition of insoluble beta pleated proteinsAll age groups Tracheobronchial formInvolvement of trachea and airwaysUpper airway obstruction, stridor, dyspneaNarrowing of the tracheal lumenNodules, plaques or wall thickening of the subepithelial trachea, which may be calcified Nodular parenchymal formLung nodule/massAsymptomaticPeripheral solitary or multiple nodulesPeripheral well circumscribed nodule/s which may be calcified Diffuse interstitial formAmyloid infiltration of pulmonary interstitiumDyspneaReticular markingsInterlobular septal thickening, which may be nodular; calcifications may be seen  **Pulmonary alveolar proteinosis**Mutations in surfactant protein or GM-CSF genesIntra-alveolar accumulation of surfactant like materialYoung to middle aged men, modest clinical symptomsDrastic appearance with bilateral perihilar airspace diseaseInterlobular septal thickening with ground-glass opacities giving a "crazy paving" appearance*CXR* chest radiography, *CT* computed tomography, *GM-CSF* granulocyte monocyte-colony stimulating factorTable 2Summary of storage lung diseasesDiseaseAetiologyPathologyRelevant clinical featuresImaging findingsCXRCT**Niemann-Pick disease**Autosomal recessive lysosomal storage disorderDeposition of lipid laden macrophages, NP cells in various organs; endogenous lipoid pneumonia in the lungsOften asymptomatic, Ashkenazi JewsReticulonodular markingsGround-glass opacity in the upper lungs and interlobular septal thickening in the lower lungs**Gaucher disease**Autosomal recessive lysosomal storage disorder with deficiency of glucocerebrosidaseDeposition of lipid laden macrophages, Gaucher cells in various organsOften asymptomatic, Ashkenazi JewsDiffuse reticular markingsInterlobular septal thickening and DIP-like reaction. May see arteriovenous shunting with hepatopulmonary syndrome**Hermansky-Pudlak syndrome**Autosomal recessive disorder with defective trafficking of intracellular vesiclesTriad of oculocutaneous albinism, platelet dysfunction and pulmonary fibrosisDyspnea, seen in Puerto-Rican populationReticular markingsPulmonary fibrosis with UIP imaging pattern*CXR* chest radiography, *CT* computed tomography, *UIP* usual interstitial pneumonia, *DIP* Desquamative interstitial pneumonia, *NP cells* Niemann Pick cells

Metabolic lung diseases {#Sec2}
=======================

HRCT technique {#Sec3}
--------------

In patients with suspected metabolic or storage lung disease, HRCT should be done as a helical acquisition at end inspiration using the thinnest collimation and reconstructed at 1.0-- to 1.5-mm slice thickness. The scan length should extend from the thoracic inlet down to the diaphragms. A high-spatial frequency kernel should be used for lung images. Contrast administration is not necessary. Technique should be standard for chest CT (typically 120 kV and automatic exposure control for mA). If significant air trapping is suspected, limited expiratory images can be obtained at 20-mm intervals from the apex to the diaphragm.

Pulmonary calcification and ossification {#Sec4}
========================================

Introduction and clinical features {#Sec5}
----------------------------------

Pulmonary calcification and ossification are the most common metabolic lung diseases detected on chest radiography and HRCT. Pulmonary calcification occurs either through dystrophic or metastatic mechanisms \[[@CR1]\]. Dystrophic calcifications form in damaged areas of lung as a result of inflammation or infection, such as tuberculosis, or in areas of previous haemorrhage or infarct. Calcification can also form in neoplasms such as chondrosarcoma or osteosarcoma as a natural process of the disease \[[@CR2]\]. Metastatic pulmonary calcification develops in areas of normal lung in patients with altered calcium and phosphate metabolism, leading to calcium deposition in the lungs and other organs such as bones and kidneys. Hypercalcaemia secondary to chronic renal failure (Fig. [1](#Fig1){ref-type="fig"}) is the most common cause of metastatic pulmonary calcification \[[@CR3]\]. Other causes include primary hyperparathyroidism, skeletal metastases and multiple myeloma \[[@CR4]\]. The various causes are summarised in Table [3](#Tab3){ref-type="table"}.Fig. 1A 65-year-old woman with metastatic calcification from chronic kidney failure. **a** AP radiograph shows dense foci of consolidation (*arrows*) in the lower lungs. **b**, **c** Unenhanced CT images show mass-like foci of calcified lung (*arrows*)Table 3Causes of pulmonary calcification and ossificationPulmonary calcification(A) Dystrophic  1. Granulomatous diseases---granulomatous infection such as histoplasmosis and tuberculosis and non-infectious causes such as sarcoidosis.  2. Other infections---viral infections such as varicella and parasitic infections such as paragonimiasis.  3. Occupational lung diseases---silicosis, coal workers' pneumoconiosis.  4. Metabolic lung diseases---amyloidosis, Pulmonary alveolar microlithiasis.  5. Vascular causes---areas of prior haemorrhage or infarction, pulmonary hypertension, arterio-venous malformation.  6. Miscellaneous---post-treatment such as radiation therapy.(B) Metastatic  1. Non-neoplastic---most common cause is hypercalcaemia in the setting of chronic renal failure. Other causes are conditions causing primary hyperparathyroidism, iatrogenic (following calcium therapy), Paget's disease.  2. Neoplastic---parathyroid carcinoma, multiple myeloma, lymphoma/leukaemia and metastases such as chondrosarcoma.Pulmonary ossification 1. Nodular type---in chronic venous congestion. 2. Dendriform type---in chronic lung insult with resultant fibrosis. 3. Bone forming neoplasms such as osteosarcoma.

Diffuse pulmonary ossification has been increasingly recognised since the advent of CT \[[@CR5]\]. Pathologically, pulmonary ossification can be classified as either nodular (NPO) or dendriform (DPO) based on the respective morphological appearances. Of the two entities, NPO is more common \[[@CR6]\].

Nodular pulmonary ossification {#Sec6}
------------------------------

Classically described with long-standing severe mitral stenosis, NPO can occur with any condition, leading to chronic pulmonary oedema and pulmonary venous hypertension \[[@CR7], [@CR8]\]. Histologically, NPO is characterised by calcified or ossified intra-alveolar masses that are usually devoid of marrow elements or fat \[[@CR6]\].

Imaging findings {#Sec7}
----------------

On radiography HRCT, small, discrete, round calcified nodules 1--5 mm in diameter are present in the mid to lower lungs (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR6]\]. The differential diagnosis in these patients includes healed varicella infection or remote disseminated granulomatous infections such as histoplasmosis.Fig. 2A 54-year-old man with fibrosing mediastinitis, mitral valve stenosis and nodular pulmonary ossification. **a** Unenhanced HRCT image shows high attenuation ground-glass opacities in the right upper and lower lobes with punctate calcifications (*arrowheads*). **b** Unenhanced HRCT image shows soft tissue thickening and dense calcification (*arrow*) at the confluence of the right pulmonary veins

Dendriform pulmonary ossification {#Sec8}
---------------------------------

Although the exact pathogenesis of DPO is unclear, the condition is postulated to be a reaction to chronic lung insult, resulting in metaplasia of pulmonary fibroblasts into bone. In contrast to NPO, DPO predominantly affects the alveolar interstitium and usually contains marrow or fat elements \[[@CR6]\]. DPO commonly develops in the setting of chronic inflammation, including interstitial fibrosis, and may also be seen in patients with a history of amyloidosis, cystic fibrosis, asbestos exposure or treatment with busulfan \[[@CR9]--[@CR12]\]. In the authors' experience, recurrent aspiration also appears to be a risk factor. DPO is most common in men in their fifth and sixth decades of life. The clinical course is usually indolent or slowly progressive \[[@CR13]\].

Imaging findings {#Sec9}
----------------

The chest radiographic findings of DPO include delicate branching linear opacities and small distinct nodules. The differential diagnosis based on radiography includes fibrosis, bronchiectasis and lymphangitic spread of tumour. HRCT findings are quite characteristic, consisting of lower lobe predominant punctate and serpentine calcifications (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}), often located in areas of co-existing lung disease such as fibrosis \[[@CR11], [@CR12]\].Fig. 3A 48-year-old man with dendriform pulmonary ossification. HRCT image shows branching and punctate calcifications (*arrowheads*) in the right middle and lower lobes. There is a background of mild reticulation and ground-glass opacity, reflecting underlying mild interstitial fibrosisFig. 4A man with asbestosis and dendriform pulmonary ossification. Prone HRCT image shows branching calcifications (*arrows*) in both lower lobes

Both NPO and DPO can show uptake of bone scanning agent (e.g. technetium-99m methylene diphosphonate) \[[@CR14]\].

Definitive diagnosis and treatment {#Sec10}
----------------------------------

Since this disorder is usually incidentally detected and affected patients are asymptomatic, no treatment is recommended. Surveillance with pulmonary function tests or chest radiography may be considered, if deemed necessary.

Pulmonary alveolar microlithiasis {#Sec11}
=================================

Introduction and clinical features {#Sec12}
----------------------------------

Pulmonary alveolar microlithiasis is a rare disease characterised by intra-alveolar deposition of microliths, which consist primarily of calcium and phosphorous \[[@CR15]\]. The aetiology is unknown, although recent studies have found an autosomal recessive trait caused by mutations of the *SLC34A2* gene in affected patients \[[@CR16]\]. Pulmonary alveolar microlithiasis occurs in all age groups. Most patients are asymptomatic, and the diagnosis is established during imaging studies for other conditions.

Imaging findings {#Sec13}
----------------

On radiography, diffuse calcified micronodules are present in both lungs, leading to a "sandstorm" appearance \[[@CR17]\]. These nodules are most prevalent in the mid to lower lungs, likely because of the increased surface area and blood supply \[[@CR18], [@CR19]\]. Interstitial thickening can also present, although this finding is clearer on HRCT. Radiography may also show a lucent subpleural line reflecting extrapleural fat between the ribs and the calcified lung, described as "the black pleura sign" \[[@CR20]\].

HRCT shows discrete calcified micronodules scattered throughout the lungs. Apparent interlobular septal thickening and calcification may also be present (Fig. [5](#Fig5){ref-type="fig"}), presumably the result of increased concentration of microliths in the periphery of the secondary pulmonary lobule \[[@CR21], [@CR22]\]. Pleural and pericardial calcification has also been described \[[@CR18], [@CR23]\]. The differential diagnosis includes PAP, sarcoidosis, pneumoconiosis, idiopathic pulmonary haemosiderosis, amyloidosis and metastatic calcification \[[@CR24], [@CR25]\].Fig. 5A man with pulmonary alveolar microlithiasis. Contrast-enhanced HRCT image shows diffuse high attenuation ground-glass opacity with superimposed septal lines (crazy-paving) (*arrowheads*) as well as foci of calcified lung consolidation (*arrows*). Courtesy of Gerald F. Abbott, M.D. (Boston, MA)

Bone scintigraphy can demonstrate radiotracer uptake in the lungs \[[@CR26]\], and magnetic resonance imaging (MRI) can show increased signal intensity of the lesions on T1-weighted images \[[@CR20]\].

Definitive diagnosis and treatment {#Sec14}
----------------------------------

Pulmonary alveolar microlithiasis can be definitively diagnosed through bronchoalveolar lavage or lung biopsy. There is no effective treatment for this condition, and prognosis is generally poor, with most patients experiencing worsening respiratory insufficiency \[[@CR18]\]. Lung transplantation may be performed, although the long-term benefits are uncertain.

Pulmonary amyloidosis {#Sec15}
=====================

Introduction and clinical features {#Sec16}
----------------------------------

Amyloidosis comprises a diverse group of metabolic disorders characterised by extracellular deposition of insoluble proteins consisting of beta-pleated sheets. Clinically, amyloidosis can be classified as either systemic or localised \[[@CR27]\]. Systemic forms of amyloidosis include primary amyloidosis, secondary amyloidosis and familial amyloidosis. Primary amyloidosis occurs in the absence of pre-existing disease, with the exception of dyscrasias (e.g. multiple myeloma and Waldenström macroglobulinemia). Secondary amyloidosis, which is the more common form, results from a number of conditions, such as chronic renal failure, chronic infection and neoplasia. Localised forms are characterised by local production of fibrillar proteins (usually amyloid light chain \[AL\] type), which can be deposited in nearly any organ. Familial amyloidosis typically presents as sensorimotor peripheral neuropathy in the second or third decade of life \[[@CR28]\]. The kidneys and heart can also be involved. In familial cardiac amyloidosis, the amyloid fibrils consist of prealbumin, a mutant of transthyretin.

Respiratory tract involvement occurs in approximately 50 % of patients with amyloidosis and is more common with the systemic form \[[@CR27]\]. Clinical signs and symptoms vary depending on whether the disease is systemic or localised. The most common form of systemic amyloidosis, the AL form, is seen in patients over 50 years of age \[[@CR29]\]. In this form, the clinical manifestations are variable as a result of multiorgan involvement, and patients may often present with non-specific symptoms such as fatigue or weight loss \[[@CR30]\]. A substantial number of patients also have cardiac involvement that may contribute to respiratory symptoms such as dyspnea. Localised amyloidosis with involvement of the tracheobronchial system typically occurs in the fifth to sixth decades of life, and affected patients may present with stridor and dyspnea \[[@CR31]\].

Imaging findings {#Sec17}
----------------

Three CT patterns of pulmonary amyloidosis have been described: tracheobronchial, nodular parenchymal and diffuse interstitial forms.

Tracheobronchial form {#Sec18}
---------------------

The most common is the tracheobronchial form, which is characterised by submucosal deposition of fibrillar protein within the airway wall. This can manifest on CT as nodules, plaques or circumferential wall thickening \[[@CR32], [@CR33]\]. The larynx, trachea, and larger bronchi (Figs. [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}) may be involved. With this form, metaplastic calcification of the nodules is fairly common. Complications such as atelectasis and pneumonia are fairly common and are largely dependent on the site of involvement. In one study, obstructive symptoms were noted in patients with upper tracheal disease, whereas those with mid-tracheal and distal airway disease presented with recurrent pneumonias or lobar or distal atelectasis \[[@CR31]\]. Also, patients with distal airway involvement may develop secondary bronchiectasis \[[@CR31]\].Fig. 6A 61-year-old man with tracheobronchial amyloidosis. Axial (**a**) and coronal reformatted (**b**) CT images show circumferential, diffuse tracheobronchial thickening with foci of mural calcification (*arrowheads*) and resultant luminal narrowingFig. 7A man with tracheobronchial amyloidosis. HRCT image shows diffuse bronchial wall thickening with mural calcifications (*arrows*) and resultant luminal narrowing. There are patchy linear foci of consolidation (*arrowhead*) in the left upper lobe resulting from obstructive pneumonia

A significant advantage of HRCT in evaluation of tracheobronchial amyloidosis is the ability to accurately assess the degree of luminal narrowing. Using volumetric acquisitions and multiplanar reconstructions, airway luminal diameters and areas and extent of wall thickening can be accurately assessed. Also, HRCT can be used to guide bronchoscopic sampling and identify sites for treatment.

The differential diagnosis is limited and includes diffuse tracheal diseases such as relapsing polychondritis, granulomatosis with polyangitis, sarcoidosis and inflammatory bowel disease \[[@CR34]--[@CR37]\]. In contrast to other diffuse tracheal diseases, relapsing polychondritis characteristically spares the posterior tracheal and bronchial membranes. Tracheobronchopathia osteochondroplastica (TBO) is an uncommon condition characterised by formation of osseous, cartilaginous or both types of nodules within the large airways, and some reports in the literature have suggested that TBO may be associated with tracheobronchial amyloidosis \[[@CR38]\]. As with relapsing polychondritis, TBO also spares the posterior airway membrane.

Nodular parenchymal form {#Sec19}
------------------------

Nodular parenchymal amyloidosis is relatively rare, with one study reporting only seven cases of nodular disease over a 13-year period \[[@CR27]\]. It is characterised by solitary or multiple well-defined, predominantly subpleural nodules measuring up to 5 cm (Figs. [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}) \[[@CR39]\]. These nodules are smoothly marginated and usually are slow growing. Cavitation may occur. As with the tracheobronchial form, calcification within the nodules is fairly common and is well depicted on HRCT \[[@CR40]\]. The differential diagnosis is broad and includes granulomatous infection or neoplasia. An association with Sjögren syndrome has been described \[[@CR41]\]. In these patients, HRCT can be helpful in assessing the nodules, as well as other manifestations such as randomly scattered cysts, bronchial wall thickening and bronchiectasis \[[@CR42]\] (Fig. [10](#Fig10){ref-type="fig"}). Rarely, cystic lung disease can be seen in the absence of Sjögren syndrome (Fig. [11](#Fig11){ref-type="fig"}).Fig. 8A 54-year-old man with nodular parenchymal amyloidosis. **a** Coronal reformatted HRCT image shows scattered punctate calcifications (*arrowheads*) in both lungs with patchy consolidation (*arrows*) in the right lung. In addition, a moderate right pleural effusion is noted. **b** Axial HRCT image shows punctate calcifications (*arrowheads*) in the lungs, a small right pleural effusion, and right paratracheal lymphadenopathy (*arrow*)Fig. 9A man with nodular parenchymal amyloidosis. Contrast enhanced CT shows multiple calcified nodules (*arrows*) and dense left lower lobe consolidationFig. 10A man with Sjögren syndrome and amyloidosis. HRCT image shows multiple cysts (*arrows*) in both lower lobes, scattered nodules (*arrowheads*), and right lower lobe consolidation. The appearance is similar to that of lymphoid interstitial pneumonia, and the two processes may coexist in the setting of Sjögren syndromeFig. 11A man with amyloidosis presenting as cystic lung disease. HRCT image shows multiple cysts (*arrows*) and scattered irregular calcified nodules (*arrowheads*)

Diffuse interstitial form {#Sec20}
-------------------------

Diffuse interstitial amyloidosis is the most rare form and is characterised by deposition of amyloid in the pulmonary interstitium. Most affected patients have systemic amyloidosis. HRCT findings in patients with this condition include reticulation and septal thickening (Fig. [12](#Fig12){ref-type="fig"}). Calcified or non-calcified micronodules may also be present \[[@CR42]\]. Differential considerations include interstitial lung disease and neoplastic diseases including lymphangitic carcinomatosis.Fig. 12A man with diffuse interstitial amyloidosis. HRCT image shows smooth interlobular septal thickening (*arrow*), predominantly in the right lung. The small right pleural effusion (*arrowhead*) is related to proven pleural amyloid deposition

Miscellaneous findings {#Sec21}
----------------------

Mediastinal and hilar lymph node enlargement can occur in isolation or as a component of systemic amyloidosis (Figs. [8b](#Fig8){ref-type="fig"} and [13](#Fig13){ref-type="fig"}) \[[@CR27], [@CR42]\]. Pleural involvement has also been reported, manifesting as pleural thickening and persistent pleural effusions (Fig. [12](#Fig12){ref-type="fig"}) \[[@CR43]\].Fig. 13A man with lymph node amyloidosis. Contrast-enhanced CT image shows bulky calcified mediastinal lymph node enlargement with severe mass effect on the superior vena cava, leading to development of venous collaterals

Functional imaging with fluorodeoxyglucose-positron emission tomography (FDG-PET) and amyloid scintigraphy with technetium-aprotinin has been shown to highlight areas of amyloid deposition, although the exact role of these techniques is still uncertain \[[@CR44], [@CR45]\].

Definitive diagnosis and treatment {#Sec22}
----------------------------------

The reference standard for diagnosing amyloidosis is histopathological confirmation of amyloid with Congo Red staining under cross-polarised light; with this staining, amyloid demonstrates apple-green birefringence \[[@CR46]\]. Treatment and prognosis depend on the type and distribution of the disease, with localised forms usually managed conservatively and systemic forms treated with chemotherapy and anti-inflammatory agents. Patients with tracheobronchial disease may be treated with debulking or excision of the lesion(s).

Pulmonary alveolar proteinosis {#Sec23}
==============================

Introduction and clinical features {#Sec24}
----------------------------------

PAP is a rare disease characterised by accumulation of surfactant-like material in the alveoli. The estimated incidence and prevalence of PAP is 3.7 per 1 million persons \[[@CR47]\]. In patients with this disease, mutations in the surfactant protein or granulocyte-macrophage colony-stimulating factor (GM-CSF) genes result in defective clearance of surfactant by alveolar macrophages \[[@CR48]\]. Three forms of PAP are recognised: autoimmune, secondary and genetic. The autoimmune type (previously called primary or idiopathic) accounts for 90 % of all cases \[[@CR49]\]. The more rare secondary form is usually associated with haematological malignancies and inhalation of toxins such as silica dust. The genetic type is exceedingly rare. In the autoimmune and secondary forms, clinical symptoms are non-specific, and nearly one-third of affected patients are asymptomatic. Most patients with PAP are young to middle-aged men \[[@CR50]\]. An association of PAP with smoking has been described \[[@CR50]\], and superimposed infections with *Nocardia, Pneumocystis jiroveci* and *Mycobacteria* have been reported \[[@CR50], [@CR51]\].

Imaging findings {#Sec25}
----------------

Imaging findings of PAP can be striking; and the clinicoradiologic discordance with modest clinical symptoms and florid imaging findings has been described \[[@CR48]\]. Chest radiography is a helpful initial imaging test for assessing patients with known or suspected PAP. Radiography typically shows bilateral patchy opacities with a perihilar to basal predominance (Fig. [14](#Fig14){ref-type="fig"}). The pattern is non-specific and can be easily mistaken for oedema and infection. However, ancillary findings associated with pulmonary oedema such as cardiomegaly and pleural effusion are usually absent. The onset of symptoms can also be used to distinguish PAP from pulmonary oedema, as PAP has an insidious onset, whereas pulmonary oedema and infection typically develop rapidly.Fig. 14A 41-year-old woman with pulmonary alveolar proteinosis. **a** PA chest radiograph shows patchy hazy opacities with some foci of more confluent opacity (*arrows*). **b**, **c** HRCT images show a geographic pattern of ground-glass opacity and superimposed septal lines ("crazy-paving")

HRCT is the imaging test of choice for known or suspected PAP. The characteristic HRCT findings for PAP are patchy or geographic areas of ground-glass opacity with superimposed septal lines, termed "crazy-paving" (Figs. [14](#Fig14){ref-type="fig"}, [15](#Fig15){ref-type="fig"}) \[[@CR52]\]. Although crazy-paving in and of itself is a non-specific finding, a geographic distribution in the correct clinical setting is virtually pathognomonic for PAP. One series reviewed the imaging findings of 98 patients with PAP \[[@CR53]\]. Of the 89 patients who underwent chest radiography, 57 (58 %) had a perihilar distribution of disease, with costophrenic and apical sparing in 65 (73 %) patients. Of the 28 patients who underwent CT, crazy-paving was present in 20 (71 %) patients, and geographic or lobular areas of sparing were present in 15 (75 %) patients with the crazy-paving. Some reports describe coexisting interstitial fibrosis in patients with PAP \[[@CR54], [@CR55]\].Fig. 15A man with pulmonary alveolar proteinosis. Axial (**a**) and coronal reformatted (**b**) HRCT images show a more diffuse pattern of crazy-paving

FDG-PET has been shown to show FDG uptake in PAP and is likely related to increased glucose utilisation in the inflammatory component \[[@CR56]\].

Definitive diagnosis and treatment {#Sec26}
----------------------------------

PAP is definitively diagnosed by staining bronchoalveolar lavage fluid, and lung biopsy is rarely required. Treatment depends on the type of PAP. Whole-lung lavage is the treatment of choice for symptomatic patients with autoimmune disease \[[@CR48]\], and secondary cases require removal of the inciting agent. Experimental therapies with granulocyte-macrophage colony-stimulating factor and rituximab have been tried and have been successful in a subset of patients \[[@CR57], [@CR58]\].

Storage lung diseases {#Sec27}
=====================

Gaucher disease {#Sec28}
---------------

### Introduction and clinical features {#Sec29}

Gaucher disease, the most common lysosomal storage disorder, results from deficiency of the enzyme glucocerebrosidase \[[@CR59]\]. Although this condition is rare worldwide, occurring in approximately 1 per 75,000 births, it occurs most frequently among Ashkenazi Jews \[[@CR60]\]. Gaucher disease leads to the accumulation of lipid-laden macrophages (Gaucher cells) in a number of organs, particularly the liver, spleen, bone marrow and lung. Lung involvement is variable, although it has been reported in severe forms of the disease \[[@CR61]\].

### Imaging findings {#Sec30}

When the interstitium is infiltrated with Gaucher cells, septal thickening may be present on HRCT (Fig. [16](#Fig16){ref-type="fig"}) \[[@CR62]\]. A desquamative interstitial pneumonia-like reaction has also been described secondary to alveolar filling with Gaucher cells \[[@CR63]\]. Plugging of the capillary walls can result in the pulmonary hypertension \[[@CR64]\]. Furthermore, long-standing liver disease may predispose the patient to hepatopulmonary syndrome with intrapulmonary vascular dilation and arteriovenous shunting \[[@CR65]\].Fig. 16A child with Gaucher disease. HRCT images shows fine linear opacities and hilar lymph node enlargement (*arrowheads*). Courtesy of Alan Brody, M.D. (Cincinnati, OH)

### Definitive diagnosis and treatment {#Sec31}

Bronchoalveolar lavage or lung biopsy can be used for definitive diagnosis of lung involvement. In general, prognosis is poor, with more than half of patients dying of respiratory failure. Possible therapeutic options include enzyme therapy and substrate reduction therapy \[[@CR66]\]. Patients with hepatopulmonary syndrome may have a worse prognosis \[[@CR67]\].

Niemann-Pick disease {#Sec32}
--------------------

### Introduction and clinical features {#Sec33}

Niemann-Pick disease refers to a group of rare autosomal recessive lysosomal storage disorders that are subclassified into types A, B, and C. Type A is the most common and has a high incidence in Ashkenazi Jews, where the carrier frequency is approximately 1 per 100 persons \[[@CR60]\]. Types A and B are caused by absence or deficiency of sphingomyelinase, respectively. Patients with Type A usually die within a few years of birth, while type B patients with residual enzyme activity often survive into adulthood \[[@CR68]\]. Type C disease is caused by mutations of *NPC1* and *NPC2* genes, which code for transmembrane proteins involved in Golgi shuttling and cholesterol binding \[[@CR68]\]. Lung involvement typically occurs in all forms of the disease, with the possible exception of the adult form (type C) \[[@CR69]\]. In patients with Niemann-Pick disease, lipid-laden macrophages called Niemann-Pick cells are deposited in various organs, including the lungs. In the lung, these cells infiltrate into and are deposited in the alveolar walls and interstitium with relative preservation of pulmonary architecture \[[@CR68]\]. Most patients with this disease present during infancy \[[@CR70]\].

### Imaging findings {#Sec34}

On HRCT, ground-glass opacity predominates in the upper lungs and interlobular septal thickening predominates in the lung bases (Fig. [17](#Fig17){ref-type="fig"}) with preservation of underlying lung architecture. Ground-glass opacity may reflect an endogenous lipoid pneumonia with partial alveolar filling (Fig. [18](#Fig18){ref-type="fig"}) \[[@CR71]\], although the exact cause for the distribution of these findings is unclear \[[@CR72]\].Fig. 17A 46-year-old woman with Niemann-Pick disease. **a** HRCT image shows ground-glass opacity with septal thickening (*arrowheads*) in the upper lobes. Small pleural effusions are present. **b** HRCT image inferiorly at the level of heart again shows ground-glass opacity with septal thickening (*arrowheads*). Also seen are bilateral small pleural effusions and adjacent atelectasis (*arrow*)Fig. 18A man with Niemann-Pick disease. **a**, **b** Contrast-enhanced CT images show extensive ground-glass opacity. Mild septal thickening (*arrows*) is also present

### Definitive diagnosis and treatment {#Sec35}

Bronchoalveolar lavage or lung biopsy can be used to demonstrate lung involvement by demonstrating the presence of characteristic Niemann-Pick cells. Treatment is generally supportive, although some reports have demonstrated the value of whole lung lavage in treating endogenous lipoid pneumonia \[[@CR72]\]. Also, haematopoietic stem cell transplantation has been reported to be successful in treating lung disease \[[@CR70]\].

Hermansky-Pudlak syndrome {#Sec36}
-------------------------

### Introduction and clinical features {#Sec37}

Hermansky-Pudlak syndrome (HPS) comprises a group of autosomal recessive disorders characterised by a triad of oculocutaneous albinism, platelet dysfunction with bleeding diathesis, and pulmonary disease \[[@CR73]\]. Although this syndrome is rare worldwide, it has the highest prevalence in northwest Puerto Rico, affecting approximately 1 in 1,800 persons \[[@CR74]\]. Seven different genes associated with HPS have been identified in humans \[[@CR75]\]. The fundamental pathophysiology of this disease is disturbed formation or trafficking of intracellular vesicles such as lysosomes and melanosomes, resulting in intracellular accumulation of ceroid-lipofuscin \[[@CR76]\]. Lung involvement in HPS is typically characterised by progressive pulmonary fibrosis. The cause of fibrosis is unclear, although it has been postulated to result from sequential injury to alveolar epithelium with the formation of lamellar bodies \[[@CR77]\]. Specifically, researchers have explored the role of type II pneumocytes in this pathology \[[@CR78]\].

### Imaging findings {#Sec38}

On HRCT, HPS manifests as reticulation, septal thickening, and ground-glass opacities, all of which can progress over time (Fig. [19](#Fig19){ref-type="fig"}). In advanced cases, peribronchovascular interstitial thickening has also been described \[[@CR79]\]. A usual interstitial pneumonia pattern is typically present on histopathology \[[@CR75]\].Fig. 19A 53-year-old man with Hermansky-Pudlak syndrome. **a**, **b** HRCT images show reticulation (*arrowheads*) and traction bronchiectasis (*arrows*) on a background of diffuse ground-glass opacity

### Definitive diagnosis and treatment {#Sec39}

Prognosis is poor in patients with lung fibrosis. There is no effective therapy for pulmonary fibrosis, although lung transplantation has been performed in selected patients \[[@CR80]\].

Conclusion {#Sec40}
==========

In summary, metabolic and storage lung diseases consist of a heterogeneous group of entities with diverse and interesting clinical and imaging manifestations. Imaging findings can often be invaluable in narrowing the differential diagnoses and pointing towards a specific diagnosis in the right clinical setting. Also, imaging tests such as HRCT have a pivotal role in assessing disease progression and also in evaluating response to therapy.
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